Manufacturing scale-up could be key to biopharmas’ response to pandemics

Although several proposals in the July 19 Berlin Declaration on equitable access to pandemic countermeasures may prove unrealistic, a commitment by IFPMA members to quickly scale up manufacturing for high volume global supply could establish a foundation on which to build capacity for future pandemics.

The declaration set forth by the International Federation of Pharmaceutical Manufacturers & Associations seeks to address the factors that limited the success of initiatives to ensure equitable access to COVID-19 countermeasures, such as inadequate upfront financing mechanisms and a lack of preparedness among developing countries. IFPMA said factors such as these continue to keep vaccines from “getting to every arm that needs it.”  ...